Last reviewed · How we verify
Reduced-dose HHT
At a glance
| Generic name | Reduced-dose HHT |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (PHASE1, PHASE2)
- Newly-diagnosed Pediatric T-cell ALL Protocol (PHASE2, PHASE3)
- Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. (PHASE2)
- Pomalidomide for the Treatment of Bleeding in HHT (PHASE2)
- Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reduced-dose HHT CI brief — competitive landscape report
- Reduced-dose HHT updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI